Viva Biotech Executes 13.91 Million-Share Buyback; Outstanding Share Capital Unchanged

Bulletin Express05-22

Viva Biotech Holdings disclosed that the company repurchased a cumulative 13.91 million ordinary shares on the Hong Kong Stock Exchange between 8 May and 22 May 2026. All repurchased shares are earmarked for cancellation but had not yet been cancelled as of 22 May 2026, leaving the issued share count unchanged at 2.13 billion shares.

The 11 on-market transactions were executed within a volume-weighted average price range of HKD 1.39–1.57 per share. The most recent trade on 22 May 2026 involved 493,500 shares at prices between HKD 1.38 and HKD 1.39, representing a cash outlay of HKD 0.69 million.

The buybacks were carried out under the share-repurchase mandate approved on 12 June 2025, which authorises Viva Biotech to repurchase up to 212.84 million shares. To date, 13.91 million shares have been utilised under this mandate, equivalent to 0.65 % of the company’s issued shares at the time the mandate was granted.

In line with Hong Kong Listing Rule 10.06(3)(a), the company is subject to a moratorium on new share issues or treasury-share sales until 21 June 2026.

With all repurchased shares still pending cancellation, Viva Biotech’s issued share capital remains at 2,129.88 million ordinary shares, and the company held no treasury shares as of the disclosure date.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123203040?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123203040","market":"hk","top_or_hot":-1,"title":"Viva Biotech Executes 13.91 Million-Share Buyback; Outstanding Share Capital Unchanged","media":"Bulletin Express","content":"<p>Viva Biotech Holdings disclosed that the company repurchased a cumulative 13.91 million ordinary shares on the Hong Kong Stock Exchange between 8 May and 22 May 2026. All repurchased shares are earmarked for cancellation but had not yet been cancelled as of 22 May 2026, leaving the issued share count unchanged at 2.13 billion shares.</p>\n<p>The 11 on-market transactions were executed within a volume-weighted average price range of HKD 1.39–1.57 per share. The most recent trade on 22 May 2026 involved 493,500 shares at prices between HKD 1.38 and HKD 1.39, representing a cash outlay of HKD 0.69 million.</p>\n<p>The buybacks were carried out under the share-repurchase mandate approved on 12 June 2025, which authorises Viva Biotech to repurchase up to 212.84 million shares. To date, 13.91 million shares have been utilised under this mandate, equivalent to 0.65 % of the company’s issued shares at the time the mandate was granted.</p>\n<p>In line with Hong Kong Listing Rule 10.06(3)(a), the company is subject to a moratorium on new share issues or treasury-share sales until 21 June 2026.</p>\n<p>With all repurchased shares still pending cancellation, Viva Biotech’s issued share capital remains at 2,129.88 million ordinary shares, and the company held no treasury shares as of the disclosure date.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech Executes 13.91 Million-Share Buyback; Outstanding Share Capital Unchanged</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech Executes 13.91 Million-Share Buyback; Outstanding Share Capital Unchanged\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-22 19:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Viva Biotech Holdings disclosed that the company repurchased a cumulative 13.91 million ordinary shares on the Hong Kong Stock Exchange between 8 May and 22 May 2026. All repurchased shares are earmarked for cancellation but had not yet been cancelled as of 22 May 2026, leaving the issued share count unchanged at 2.13 billion shares.</p>\n<p>The 11 on-market transactions were executed within a volume-weighted average price range of HKD 1.39–1.57 per share. The most recent trade on 22 May 2026 involved 493,500 shares at prices between HKD 1.38 and HKD 1.39, representing a cash outlay of HKD 0.69 million.</p>\n<p>The buybacks were carried out under the share-repurchase mandate approved on 12 June 2025, which authorises Viva Biotech to repurchase up to 212.84 million shares. To date, 13.91 million shares have been utilised under this mandate, equivalent to 0.65 % of the company’s issued shares at the time the mandate was granted.</p>\n<p>In line with Hong Kong Listing Rule 10.06(3)(a), the company is subject to a moratorium on new share issues or treasury-share sales until 21 June 2026.</p>\n<p>With all repurchased shares still pending cancellation, Viva Biotech’s issued share capital remains at 2,129.88 million ordinary shares, and the company held no treasury shares as of the disclosure date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1123203040","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123203040","pubTimestamp":1779447842,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Viva Biotech Holdings disclosed that the company repurchased a cumulative 13.91 million ordinary shares on the Hong Kong Stock Exchange between 8 May and 22 May 2026. All repurchased shares are...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物"},"translate_title":"维亚生物执行1391万股回购；已发行股本不变","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"Viva Biotech Holdings disclosed that the company repurchased a cumulative 13.91 million ordinary shares on the Hong Kong Stock Exchange between 8 May and 22 May 2026. All repurchased shares are earmarked for cancellation but had not yet been cancelled as of 22 May 2026, leaving the issued share count unchanged at 2.13 billion shares.\nThe 11 on-market transactions were executed within a volume-weighted average price range of HKD 1.39–1.57 per share. The most recent trade on 22 May 2026 involved 493,500 shares at prices between HKD 1.38 and HKD 1.39, representing a cash outlay of HKD 0.69 million.\nThe buybacks were carried out under the share-repurchase mandate approved on 12 June 2025, which authorises Viva Biotech to repurchase up to 212.84 million shares. To date, 13.91 million shares have been utilised under this mandate, equivalent to 0.65 % of the company’s issued shares at the time the mandate was granted.\nIn line with Hong Kong Listing Rule 10.06(3)(a), the company is subject to a moratorium on new share issues or treasury-share sales until 21 June 2026.\nWith all repurchased shares still pending cancellation, Viva Biotech’s issued share capital remains at 2,129.88 million ordinary shares, and the company held no treasury shares as of the disclosure date.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123203040","isCrawlerRequest":true}